In the case of CD20-positive B-NHL, the chemotherapy is combined with anti-CD20 monoclonal antibodies, rituximab or obinutuzumab, while CD30-positive T-cell lymphomas are treated with the combination of conventional chemotherapy and anti-CD30 antibody–drug conjugate brentuximab vedotin [4,5]. Here, TNFRSF8 is linked to T-cell non-Hodgkin lymphoma.